logo

XCUR

Exicure
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 0
Sell signal 3
Bearish Engulfing
Price Hits New Low
Price Hits 52-week low

Key Stats

--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--

About XCUR

Exicure, Inc.

An early-stage biotechnology company that developing nucleic acid therapies targeting RNA to address neurological disorders and hair loss disorders

Pharmaceutical
07/09/2015
07/31/2019
NASDAQ Stock Exchange
7
12-31
Common stock
2430 N. Halsted St., Chicago, IL 60614
--
Exicure, Inc., was founded on July 9, 2015. The company is a clinical-stage biotechnology company that develops treatments for immuno-oncology, inflammatory diseases and genetic diseases based on its proprietary spherical nucleic acid (SNA) technology.

Company Financials

EPS

XCUR has released its 2023 Q2 earnings. EPS was reported at -0.68, versus the expected 0.00, missing expectations. The chart below visualizes how XCUR has performed over recent quarters, highlighting trends in earnings surprises.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime